Abstract
For the past several decades, markers of cellular proliferation in breast cancer have been postulated to indicate prognosis and predict benefits from antineoplastic therapies. The most common method to measure cellular proliferation by Ki-67 is immunohistochemistry (IHC) based assays. However, analytical issues have hindered the widespread adoption of these measures in patient care. The recent monarch E clinical trial prospectively investigated Ki-67 as a biomarker of cyclin-dependent kinase inhibitor (CDKI), Abemaciclib in the adjuvant setting. It established the benefit of CDKI in high-risk ER-positive breast cancer patients with Ki-67 expression >20%, which promoted the increased clinical demand for routine Ki-67 testing in pathology laboratories. This review summarizes some recent developments and practical issues for Ki-67 evaluation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
